Cytokinetics, Inc.
Cytokinetics Reports Q1 2024 Financial Results and Initiates Pediatric HCM Trial
Summary
Cytokinetics, Incorporated reported its first quarter 2024 financial results, showing a net loss of $135.6 million, or $1.33 per share, compared to a net loss of $131.3 million, or $1.38 per share, for the same period in 2023. The company announced topline data from the Phase 1 study of CK-586 and initiated enrollment in the CEDAR-HCM clinical trial, a study of aficamten in pediatric patients with obstructive hypertrophic cardiomyopathy (HCM). Financial results and clinical updates were detailed in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement